Newly Defined Cancer Driver FOXA1


A new study from researchers at MCTP showed that the alterations in the gene FOXA1 fall into three structural classes that diverge in clinical incidence and genetic co-alteration profile to drive prostate cancer. FOXA1 was previously known to be mutated in prostate cancer but its biological functions were poorly understood. Using RNA sequencing data from 1,546 prostate cancer samples from multiple collections, including from MI-ONCOSEQ clinical sequencing study, FOXA1’s role as a driver oncogene has been further elucidated.

Read more.